Developer docs
API playgroundTry for free, no card

Search company profiles

SideROS

Full company profile

uuid0004fox

Namestring
SideROS
Websiteurl
sideros.bio
Company typeenum
Private
Founded yearint
2019
Short descriptiontext

SideROS is an early-stage, privately held French biotechnology company founded in 2019 in Paris, operating with a 1–10 person team led by founder Raphaël Rodriguez and COO Lucie Mondoulet, and funded to date primarily by 2020 non-dilutive grants from Bpifrance and Région Ile-de-France alongside a small seed round.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biotechnology research, drug discovery, cancer therapeutics, preclinical development, life sciences
Industry1 code
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Biotechnology
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SideROS is a privately held biotechnology company based in Paris, France, founded in 2019. The company operates in the life sciences sector with a workforce of 1-10 employees. Specific product, pipeline, and scientific focus details are not publicly disclosed in available source material.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeDirect peer
Description

French-listed biotech developing immunology/epicutaneous-delivery products out of academic science. Comparable French biotech peer with similar founder-from-academia origin and Bpifrance-style public funding in its history.

TypeDirect peer
Description

US-based clinical-stage biotech focused on hematologic diseases driven by iron metabolism. Most comparable to SideROS given the shared focus on iron-biology mechanisms and translational drug development on the same biological axis the founder's lab works on.

TypeEmerging player
Description

Toulouse-based publicly-listed French biotech developing bio-HDL-based therapeutics, with a focus on metabolic and ophthalmology indications. A regional French peer of similar small-cap size operating in translational biotech, useful as a comparable for early-stage French biotech public/private dynamics.

TypeBroad incumbent
Description

Paris-headquartered global pharma with deep oncology, immunology, and rare-disease R&D. Relevant incumbent comparator for talent, partnership, and M&A pathways for Paris-based biotechs in oncology, including potential future collaboration with SideROS.

TypeBroad incumbent
Description

Paris-headquartered global specialty pharma with significant oncology and rare-disease franchises. Acts as a potential acquirer / licensing partner for French oncology biotechs like SideROS, and is the relevant incumbent comparator for any partnership or exit path.

6Transgene
TypeDirect peer
Description

French clinical-stage biotech developing immunotherapies (oncolytic viruses, TCR therapies) for cancer. A direct oncology-focused French biotech peer with overlapping institutional investors and licensing/exit optionality into major EU pharma.

TypeDirect peer
Description

Paris-based clinical-stage gene-editing and cell-therapy biotech. Relevant French peer with shared academic-founder dynamics, Paris HQ, and Bpifrance/public-funder backing, providing a comparable development and capital-structure reference point.

8Innate Pharma
TypeDirect peer
Description

Marseille-based publicly listed French biotech developing immuno-oncology therapeutics. Comparable as a French oncology-biotech peer at similar development stages and ecosystem (public French biotech funding, academic founders, French VC backing).

TypeDirect peer
Description

French publicly-listed biotech with metabolic-disease pipeline. Comparable as a French for-profit biotech that leverages academic science and public French funding ecosystems, providing a regional governance and funding benchmark.

TypeBroad incumbent
Description

French privately-held global pharma with oncology as a core franchise. Comparable incumbent for partnership/licensing dynamics for French oncology biotechs, and a logical partner/counterparty for any platform originating from Institut Curie science.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SideROS

Biotechnologysideros.bio

SideROS is an early-stage, privately held French biotechnology company founded in 2019 in Paris, operating with a 1–10 person team led by founder Raphaël Rodriguez and COO Lucie Mondoulet, and funded to date primarily by 2020 non-dilutive grants from Bpifrance and Région Ile-de-France alongside a small seed round.

SideROS firmographics

Firmographics
Name
SideROS
Website
https://sideros.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
SideROS is an early-stage, privately held French biotechnology company founded in 2019 in Paris, operating with a 1–10 person team led by founder Raphaël Rodriguez and COO Lucie Mondoulet, and funded to date primarily by 2020 non-dilutive grants from Bpifrance and Région Ile-de-France alongside a small seed round.
Ownership category
akta.pro rank

SideROS industry classification

Industry
Product category
Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Biotechnology research
  • Drug discovery
  • Cancer therapeutics
  • Preclinical development
  • Life sciences

Where SideROS is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

SideROS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

SideROS product offering

Product offering

Core offering

SideROS is a privately held biotechnology company based in Paris, France, founded in 2019. The company operates in the life sciences sector with a workforce of 1-10 employees. Specific product, pipeline, and scientific focus details are not publicly disclosed in available source material.

Differentiator

Problem solved

Functional benefit

Companies that use SideROS

Customer profile

Ideal customer profiles1 record

SideROS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

SideROS competitors and assessment

Company assessment

Direct peers

  • DBV Technologies: French-listed biotech developing immunology/epicutaneous-delivery products out of academic science. Comparable French biotech peer with similar founder-from-academia origin and Bpifrance-style public funding in its history.
  • Disc Medicine: US-based clinical-stage biotech focused on hematologic diseases driven by iron metabolism. Most comparable to SideROS given the shared focus on iron-biology mechanisms and translational drug development on the same biological axis the founder's lab works on.
  • Transgene: French clinical-stage biotech developing immunotherapies (oncolytic viruses, TCR therapies) for cancer. A direct oncology-focused French biotech peer with overlapping institutional investors and licensing/exit optionality into major EU pharma.
  • Cellectis: Paris-based clinical-stage gene-editing and cell-therapy biotech. Relevant French peer with shared academic-founder dynamics, Paris HQ, and Bpifrance/public-funder backing, providing a comparable development and capital-structure reference point.
  • Innate Pharma: Marseille-based publicly listed French biotech developing immuno-oncology therapeutics. Comparable as a French oncology-biotech peer at similar development stages and ecosystem (public French biotech funding, academic founders, French VC backing).
  • Genfit: French publicly-listed biotech with metabolic-disease pipeline. Comparable as a French for-profit biotech that leverages academic science and public French funding ecosystems, providing a regional governance and funding benchmark.

Emerging players

  • Abionyx Pharma: Toulouse-based publicly-listed French biotech developing bio-HDL-based therapeutics, with a focus on metabolic and ophthalmology indications. A regional French peer of similar small-cap size operating in translational biotech, useful as a comparable for early-stage French biotech public/private dynamics.

Broad incumbents

  • Sanofi: Paris-headquartered global pharma with deep oncology, immunology, and rare-disease R&D. Relevant incumbent comparator for talent, partnership, and M&A pathways for Paris-based biotechs in oncology, including potential future collaboration with SideROS.
  • Ipsen: Paris-headquartered global specialty pharma with significant oncology and rare-disease franchises. Acts as a potential acquirer / licensing partner for French oncology biotechs like SideROS, and is the relevant incumbent comparator for any partnership or exit path.
  • Servier: French privately-held global pharma with oncology as a core franchise. Comparable incumbent for partnership/licensing dynamics for French oncology biotechs, and a logical partner/counterparty for any platform originating from Institut Curie science.

Market position

Customer concentration

SideROS social profiles

Digital presence

SideROS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SideROS leadership team

Management profile

Number of profiles

Profiles2 records

SideROS funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SideROS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SideROS

What does SideROS do?

SideROS is a privately held biotechnology company based in Paris, France, founded in 2019. The company operates in the life sciences sector with a workforce of 1-10 employees. Specific product, pipeline, and scientific focus details are not publicly disclosed in available source material.

Is SideROS a public or private company?

SideROS is a private company. It is classified as venture growth investor backed and is currently operating.

When was SideROS founded?

SideROS was founded in 2019. It employs 1 to 10 people.

Where is SideROS based?

SideROS is headquartered in Paris, France, in the Europe region.

Who are SideROS's main competitors?

Direct peers on record are DBV Technologies, Disc Medicine, Transgene, Cellectis, Innate Pharma and Genfit. Abionyx Pharma is listed as an emerging player. Broad incumbents are Sanofi, Ipsen and Servier.

Does SideROS have an API?

No public API is recorded for SideROS.

What industry is SideROS in?

SideROS's product category is Biotechnology. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals